Table 3 Demographics and descriptive characteristics of medication use, for adherent versus non-adherent users as defined by three different operational definitions

Age

Mean (SD)

74.7 (6.7)

75.1 (7.1)

0.093

74.9 (6.9)

75.4 (7.1)

0.084

74.7 (6.8)

75.3 (7.1)

0.127

65-69 years

65-69 years 143 (29.9%)

65–69 years 143 (29.9%) 488 (28.4%

0.287

272 (29.7%)

359 (28.0%)

0.556

161 (30.2%)

470 (28.2%)

0.589

70–74 years

131 (27.4%)

423 (24.7%)

240 (26.2%)

315 (24.6%)

140 (26.3%)

415 (24.9%)

75–79 years

96 (20.0%)

365 (21.3%)

191 (20.9%)

273 (21.3%)

113 (21.2%)

351 (21.1%)

80–84 years

71 (14.8%)

252 (14.7%)

126 (13.8%)

197 (15.4%)

71 (13.3%)

252 (15.1%)

85+ years

38 (7.9%)

188 (11.0%)

87 (9.5%)

139 (10.8%)

48 (9.0%)

178 (10.7%)

Sex

Male

Male 225 (47.0%)

773 (45.1%)

0.468

418 (45.6%)

581 (45.3%)

0.896

266 (49.9%)

733 (44.0%)

0.019

Urban/Rural

Urban

271 (56.6%)

1013 (59.0%)

0.299

520 (56.8%)

768 (59.9%)

0.204

296 (55.5%)

992 (59.5%)

0.253

Rural

200 (41.8%)

664 (38.7%)

379 (41.4%)

485 (37.8%)

225 (42.2%)

639 (38.4%)

Missing

8 (1.7%)

39 (2.3%)

17 (1.9%)

30 (2.3%)

12 (2.3%)

35 (2.1%)

Income

quintile

1 (Lowest)

100 (20.9%)

332 (19.4%)

0.284

169 (18.5%)

264 (20.6%)

0.283

108 (20.3%)

325 (19.5%)

0.031

2

135 (28.2%)

384 (22.4%)

237 (25.9%)

282 (22.0%)

151 (28.3%)

360 (22.1%)

3

98 (20.5%)

367 (21.4%)

194 (21.2%)

272 (21.2%)

106 (19.9%)

360 (21.6%)

4

73 (15.2%)

301 (17.5%)

147 (16.1%)

228 (17.8%)

73 (13.7%)

302 (18.1%)

5

65 (13.6%)

293 (17.1%)

152 (16.6%)

207 (16.1%)

83 (15.6%)

276 (16.6%)

Missing

8 (1.7%)

39 (2.3%)

17 (1.9%)

30 (2.3%)

12 (2.3%)

35 (2.1%)

Comorbidities

MI

19 (4.0%)

77 (4.5%)

0.705

39 (4.3%)

48 (4.5%)

0.833

22 (4.1%)

75 (4.5%)

0.809

CHF

24 (5.0%)

97 (5.7%)

0.651

45 (4.9%)

76 (5.9%)

0.343

30 (5.6%)

91 (5.5%)

0.913

CVA

23 (4.8%)

72 (4.2%)

0.611

42 (4.6%)

53 (4.1%)

0.671

23 (4.3%)

72 (4.3%)

1.000

Dementia

5 (1.0%)

31 (1.8%)

0.311

9 (1.0%)

28 (2.2%)

0.042

7 (1.3%)

30 (1.8%)

0.563

Renal Failure

7 (1.5%)

26 (1.5%)

1.000

13 (1.4%)

20 (1.6%)

0.860

9 (1.7%)

24 (1.4%)

0.684

Charlson

Comorbidities

0

262 (54.7%)

930 (54.2%)

0.760

508 (55.5%)

685 (53.4%)

0.521

286 (53.7%)

907 (54.4%)

0.203

1

169 (35.3%)

629 (36.7%)

321 (35.0%)

480 (37.4%)

187 (35.1%)

614 (36.9%)

2+

48 (10.0%)

157 (9.2%)

87 (9.5%)

118 (9.2%)

60 (11.3%)

145 (8.7%)

New Users

144 (30.1%)

594 (34.6%)

0.063

325 (35.5%)

415 (32.4%)

0.131

200 (37.5%)

540 (32.4%)

540 (32.4%)

Monotherapy

332 (69.3%)

1090 (63.5%)

0.020

401 (43.8%)

1021 (79.6%)

<0.001

401 (75.2%)

1021 (61.3%)

<0.001

Maximum

Number of

Concurrent

Medications

1

175 (36.5%)

673 (39.2%)

0.649

259 (28.3%)

589 (45.9%)

<0.001

241 (45.2%)

607 (36.4%)

<0.001

2

194 (40.5%)

627 (36.5%)

384 (41.9%)

439 (34.2%)

205 (38.5%)

618 (37.1%)

3

83 (17.3%)

315 (18.4%)

204 (22.3%)

195 (15.2%)

69 (13.0%)

69 (13.0%)

4

26 (5.4%)

90 (5.2%)

66 (7.2%)

51 (4.0%)

18 (3.4%)

99 (5.9%)

5

1 (0.2%)

9 (0.5%)

3 (0.3%)

7 (0.6%)

0 (0.0%)

10 (0.6%)

6

0 (0.0%)

2 (0.1%)

0 (0.0%)

2 (0.2%)

0 (0.0%)

2 (0.1%)